Connect Biopharma reported positive topline preliminary results from its Phase 1 clinical pharmacology study of intravenous rademikibart, with a 300 mg dose administered via a ~2-minute IV. The data is early (Phase 1) and therefore carries typical clinical and regulatory risk, but the positive topline should act as a modest near-term catalyst for CNTB shares.
Connect Biopharma reported positive topline preliminary results from its Phase 1 clinical pharmacology study of intravenous rademikibart, with a 300 mg dose administered via a ~2-minute IV. The data is early (Phase 1) and therefore carries typical clinical and regulatory risk, but the positive topline should act as a modest near-term catalyst for CNTB shares.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
